Blaes Anne, Konety Suma, Hurley Peter
Division of Hematology/Oncology/Transplantion, University of Minnesota, 420 Delaware Street, S.E., MMC 480, Minneapolis, MN, 55455, USA.
Division of Cardiology, University of Minnesota, Minneapolis, MN, USA.
Curr Treat Options Cardiovasc Med. 2016 Apr;18(4):25. doi: 10.1007/s11936-016-0447-9.
Survivors of hematopoietic stem cell transplant (HSCT) are at significant risk for cardiac disease and cardiac complications. While there may be cardiac complications during the acute period of HSCT, long-term survivors remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and arrhythmias is warranted pretransplant. For those with risk factors, particularly a history of cardiovascular disease or atrial fibrillation, cardiology consultation is warranted in the pretransplantation period. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and hyperlipidemia is warranted in HSCT survivors as well; early and aggressive treatment of left ventricular dysfunction is warranted. Collaboration between hematology/oncology and cardiology through a cardio-oncology clinic is an optimal way to help manage these patients.
造血干细胞移植(HSCT)幸存者面临着患心脏病和心脏并发症的重大风险。虽然在HSCT急性期可能会出现心脏并发症,但长期存活者患心血管疾病的风险仍然至少比普通人群高四倍。移植前有必要积极筛查糖尿病、高血压和心律失常等心脏危险因素。对于有危险因素的患者,尤其是有心血管疾病或心房颤动病史的患者,在移植前期有必要咨询心脏病专家。HSCT幸存者也有必要积极筛查糖尿病、高血压和高脂血症等心脏危险因素;有必要对左心室功能障碍进行早期积极治疗。通过心脏肿瘤诊所,血液学/肿瘤学与心脏病学之间的合作是帮助管理这些患者的最佳方式。